Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M307026200 on September 2, 2003

J. Biol. Chem., Vol. 278, Issue 45, 44868-44873, November 7, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/45/44868    most recent
M307026200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDearmon, E. L.
Right arrow Articles by Ervasti, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDearmon, E. L.
Right arrow Articles by Ervasti, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Core 1 Glycans on {alpha}-Dystroglycan Mediate Laminin-induced Acetylcholine Receptor Clustering but Not Laminin Binding*

Erin L. McDearmon{ddagger}, Ariana C. Combs§, and James M. Ervasti{ddagger}§

From the {ddagger}Graduate Program in Molecular and Cellular Pharmacology and the §Department of Physiology, University of Wisconsin-Madison Medical School, Madison, Wisconsin 53706

Received for publication, July 1, 2003 , and in revised form, August 15, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Although unique O-linked oligosaccharides on {alpha}-dystroglycan are important for binding to a variety of extracellular ligands, the function(s) of more generic carbohydrate structures on {alpha}-dystroglycan remain unclear. Recent studies suggest a role for glycoconjugates bearing the core 1 disaccharide Gal{beta}(1–3)GalNAc in acetylcholine receptor (AChR) clustering on the surface of muscle cells. Here, we report experiments demonstrating that the core 1-specific lectin jacalin almost completely abrogated laminin-induced AChR clustering in C2C12 myotubes and that {alpha}-dystroglycan was the predominant jacalin-binding protein detected in C2C12 myotube lysates. Although jacalin likely inhibited laminin-induced AChR clustering by directly binding to {alpha}-dystroglycan, jacalin had no effect on laminin binding to the myotube surface or to {alpha}-dystroglycan. Like jacalin, peanut agglutinin lectin also binds the core 1 disaccharide but not when it is terminally sialylated as expressed on {alpha}-dystroglycan. We show that C2C12 {alpha}-dystroglycan bound to peanut agglutinin only after digestion with neuraminidase. Simultaneous treatment of myotubes with neuraminidase and endo-O-glycosidase diminished {alpha}-dystroglycan binding to peanut agglutinin and inhibited neuraminidase-induced AChR clustering. We conclude that sialylated core 1 oligosaccharides of {alpha}-dystroglycan are important for laminin-induced AChR clustering and that their function in this process is distinct from the established role of {alpha}-dystroglycan oligosaccharides in laminin binding.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The dystroglycan complex was originally identified as a component of the skeletal muscle dystrophin-glycoprotein complex, which spans the sarcolemma of muscle cells and physically couples the actin cytoskeleton with the extracellular matrix (1–3). The dystroglycan complex consists of {alpha}-dystroglycan, a highly glycosylated extracellular protein that binds to several extracellular ligands, and {beta}-dystroglycan, a single-pass transmembrane protein that links cytoplasmic dystrophin with {alpha}-dystroglycan (3). Both dystroglycan subunits are encoded by a single highly conserved pro-peptide that is proteolytically processed into {alpha}- and {beta}-dystroglycan, which remain stably associated through non-covalent interactions (3). Like muscle deficient in dystrophin or other core components in the dystrophin-glycoprotein complex (1, 2), deficiency of the dystroglycan complex in skeletal muscle results in compromised sarcolemmal integrity (4, 5). Thus, it is generally thought that one important function of the dystroglycan complex in skeletal muscle is to mechanically protect the sarcolemma against shear stresses imposed during muscle contraction. However, the dystroglycan complex has also been linked with more dynamic developmental or pathological processes (6). In skeletal muscle, several studies have implicated the dystroglycan complex in either the formation or maintenance of acetylcholine receptor (AChR)1 and acetylcholinesterase dense specializations within the motor endplate of the neuromuscular junction (4, 7–10).

O-linked oligosaccharides of unknown structure are clearly important for {alpha}-dystroglycan binding to its extracellular ligands as well as its function in vivo because mutations in glycosyltransferases that post-translationally modify {alpha}-dystroglycan result in loss of extracellular ligand binding activity and muscular dystrophy (3). {alpha}-Dystroglycan is also modified by more generic N-linked glycans and sialylated core 1 oligosaccharides with the structure SiaA{alpha}(2–3)Gal{beta}(1–3)GalNAc (11). However, enzymatic removal of these glycans has no effect on {alpha}-dystroglycan binding to laminins (12), agrin (13), or neurexins (14). Recently, Martin and colleagues (15, 16) have reported data suggesting that the common core 1 disaccharide Gal{beta}(1–3)GalNAc may play a role in AChR clustering. Most relevant to the current study, the core 1-reactive lectin peanut agglutinin was demonstrated to completely inhibit AChR clustering induced by neuraminidase treatment of myotubes (15, 16). However, the core 1-modified glyconjugate(s) important for neuraminidase-induced AChR clustering and blocked by peanut agglutinin were not identified. Here, we report that the core 1-specific lectin jacalin bound predominantly to {alpha}-dystroglycan in C2C12 myotubes and inhibited laminin-induced AChR clustering. We further demonstrate that {alpha}-dystroglycan was the predominant peanut agglutinin-binding protein detected in neuraminidase-treated C2C12 myotubes and that both {alpha}-dystroglycan binding to peanut agglutinin and neuraminidase-induced AChR clustering were dramatically inhibited by endo-O-glycosidase digestion. Additional experiments indicate that the sialylated core 1 oligosaccharides of {alpha}-dystroglycan play a role in laminin-induced AChR clustering through a mechanism independent from oligosaccharide-mediated binding of {alpha}-dystroglycan to laminin.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—The C2C12 cell line was obtained from ATCC and used between 3 and 7 passages. Proliferating cells were grown in 10 cm dishes or on poly-L-lysine-coated coverslips with Dulbecco's modified Eagle's medium (Cellgro, Fisher Scientific) containing 10% fetal bovine serum (Hyclone, Logan, UT) plus 1% antibiotic/antimycotic (Sigma) at 37 °C in a humid atmosphere of 5–10% CO2. After reaching confluency, the media was switched to Dulbecco's modified Eagle's medium containing 2% equine serum (Hyclone) plus 1% antibiotic/antimycotic. Cells were cultured until full differentiation to multi-nucleate myotubes was observed morphologically (4 days) with fresh media exchanged every 2 days.

Analysis of AChR Clustering—3-day old C2C12 myotubes grown on poly-L-lysine-coated glass coverslips were incubated with 120 nM laminin-1, 50 µg/ml jacalin lectin (EY Labs, San Mateo, CA), or both diluted in media for 18 h at 37 °C. Cells were rinsed with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, and incubated at 37 °C for 1 h with 500 ng/ml Alexa488-bungarotoxin (Molecular Probes, Eugene, OR) diluted in media. Stained cells were rinsed twice in PBS and fixed in 4% paraformaldehyde for 10 min at room temperature. Fixed cells were rinsed in PBS and mounted on slides for immunofluorescence analysis. In addition, 4-day-old C2C12 myotubes were treated with 0.1 unit/ml Clostridium perfringens neuraminidase in the absence or presence of 15 milliunits/ml endo-O-glycosidase for 2 h at 37 °C. Cells were rinsed twice with media and fixed and stained as described above. Fluorescence images were collected with a Bio-Rad MRC 1000 confocal microscope (Keck Center for Biological Imaging), or Zeiss CFL 25 fluorescence microscope using a 40x oil immersion objective and the number of AChR quantitated as previously described (17). All images were re-sized and cropped using Adobe Photoshop 5.0 and imported into CorelDraw 10 for figure preparation.

Myotube Solubilization and Lectin Chromatography—Differentiated C2C12 myotubes were rinsed twice with 37 °C PBS and scraped off each dish into 5 ml of ice-cold PBS containing the following protease inhibitors: 100 µg/ml benzamidine, 40 µg/ml phenylmethylsulfonyl fluoride, 0.5 µg/ml leupeptin, 0.5 µg/ml aprotinin, 1 mM iodoacetamide, and 0.5 µg/ml pepstatin A. Cells were pelleted by brief centrifugation and solubilized in 0.5 ml/dish of 1% Triton buffer (50 mM Tris-HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2, 100 µg/ml benzamidine, 40 µg/ml phenylmethylsulfonyl fluoride, 0.5 µg/ml leupeptin, 0.5 µg/ml aprotinin, 1 mM iodoacetamide, 0.5 µg/ml pepstatin A, 1% Triton X-100) containing 150 mM NaCl (unless otherwise noted). The resuspended cell pellet was incubated at 4 °C for 1 h with end-over-end mixing followed by centrifugation for 15 min at 10,000 x g. 0.2 ml of Triton-solubilized C2C12 myotube lysate was incubated overnight at 4 °C with 50 µl of jacalinagarose or peanut agglutinin-agarose beads (EY Labs) that were preequilibrated in wash buffer (50 mM Tris-HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2, 150 mM NaCl, 100 µg/ml benzamidine, 40 µg/ml phenylmethylsulfonyl fluoride, 0.1% Triton X-100). The beads were pelleted by brief centrifugation and the void volumes retained for Western blot analysis. Lectin beads were then washed extensively with wash buffer and bound proteins eluted by incubation with Laemmli sample buffer (LSB, 3% SDS, 0.115 M sucrose, 65 mM Tris-HCl, pH 6.8, and 1% {beta}-mercaptoethanol) containing 0.1 M lactose.

To determine the effects of neuraminidase and endo-O-glycosidase treatment on the peanut agglutinin-reactivity of {alpha}-dystroglycan, C2C12 myotubes were incubated for 2 h at 37 °C with 0.1 units/ml C. perfringens neuraminidase (Roche Applied Science) in the absence or presence of 15 milliunits/ml endo-O-glycosidase (Prozyme, San Leandro, CA). Cells were rinsed twice with 37 °C PBS, harvested, and solubilized for peanut agglutinin-agarose chromatography as described above.

Immunofluorescence Analysis of {beta}-Dystroglycan Distribution and Laminin-1 Binding to C2C12 Myotubes—3-day-old C2C12 myotubes were incubated for 18 h at 37 °C in the absence or presence of 50 µg/ml jacalin, 120 nM laminin-1, or both jacalin plus laminin-1 diluted in Dulbecco's modified Eagle's medium containing 2% equine serum. To assess the effect of jacalin on the distribution of {beta}-dystroglycan, control and jacalin-treated myotubes were rinsed with PBS, fixed in 4% paraformaldehyde for 10 min at room temperature, and permeabilized with 0.2% Triton X-100 for 10 min. After blocking overnight at 4 °C with 3% bovine serum albumin in PBS, myotubes were incubated with mouse monoclonal antibody NCL-{beta}-DG to {beta}-dystroglycan (Vector Laboratories, Burlingame, CA) in 1% bovine serum albumin/PBS for 2 h at room temperature. Myotubes were rinsed three times with PBS followed by an incubation with Alexa488-conjugated anti-mouse antibodies (Molecular Probes) diluted in 1% bovine serum albumin for 1 h at room temperature. Cells were rinsed and mounted on slides for fluorescence microscopy. To assess the effect of jacalin on laminin-1 binding to C2C12 myotubes, control, laminin-1-treated, and laminin-1 plus jacalin-treated myotubes were rinsed with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, and fixed in 4% paraformaldehyde for 10 min at room temperature. Myotube-bound laminin-1 was detected with an affinity-purified rabbit polyclonal antibody raised against mouse laminin-1 (Sigma) and Alexa488-conjugated anti-rabbit antibodies as described above. Images were collected and processed for inclusion in figures as described above.

Western Blot Analysis of Laminin-1 Binding to C2C12 Myotubes— Control, laminin-1-treated, and laminin-1 plus jacalin-treated myotubes were rinsed with 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, and solubilized with Laemmli sample buffer. The relative laminin {alpha}1 chain immunoreactivity present in equal amounts of total myotube protein was assessed by SDS-polyacrylamide gel electrophoresis and Western blotting using an affinity-purified rabbit polyclonal antibody raised against mouse laminin-1.

Analysis of Laminin-1 Binding to {alpha}-Dystroglycan—The effect of jacalin on laminin-1 binding to {alpha}-dystroglycan was also assessed by two methods. First, polystyrene microtiter wells coated overnight at 4 °C with 0.1 µg of {alpha}-dystroglycan purified from rabbit skeletal muscle were blocked with 3% bovine serum albumin in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 and incubated with 4 nM laminin-1 in the presence of increasing concentrations of jacalin. Laminin-1 binding was detected with affinity-purified rabbit polyclonal antibodies against laminin-1, followed by HRP-conjugated anti-rabbit secondary and color development with 3,3',5,5'-tetramethylbenzidine (Bio-Rad Laboratories, Hercules, CA). Color development was quantitated kinetically at 655 nm using a Molecular Dynamics Spectramax 340UV/Vis microplate reader. As a positive control for inhibition, a parallel assay was performed in the presence of increasing concentrations of purified monoclonal antibody IIH6 (the kind gift of Dr. Kevin Campbell), which was previously shown to inhibit laminin-1 binding to {alpha}-dystroglycan (12). In the second assay, C2C12 myotubes were solubilized in 50 mM Tris-HCl, pH 7.4, 1 mM CaCl2, 1 mM MgCl2, 100 µg/ml benzamidine, 40 µg/ml phenylmethylsulfonyl fluoride, 1% Triton X-100, and 50 mM NaCl to facilitate laminin binding to {alpha}-dystroglycan in the presence of detergent (12), and lysates were incubated overnight at 4 °C with jacalinagarose either alone or in the presence of 0.25 µg/ml or 0.5 µg/ml purified laminin-1. Beads were washed extensively, and bound proteins were eluted with Laemmli sample buffer. To determine whether laminin-1 bound directly to jacalin-agarose, purified laminin-1 was diluted to 0.5 µg/ml in 50 mM Tris, pH 7.4, 150 mM NaCl, and 1 mM CaCl2, and 100 µl was incubated overnight with 20 µl of jacalin-agarose at 4 °C. Jacalin-agarose was washed and bound proteins eluted as described above. The amount of laminin {alpha}1 chain and {alpha}-dystroglycan present in the starting material, voids, and lectin-bound fractions was assessed by SDS-polyacrylamide gel electrophoresis and Western blotting.

SDS-PAGE and Western blotting—Samples were resolved by SDS-polyacrylamide gel electrophoresis and stained with Coomassie blue or transferred to nitrocellulose as previously described (11). Western blotting was performed with either monoclonal antibody IIH6 to {alpha}-dystroglycan (11), or affinity-purified rabbit polyclonal antibodies against laminin-1 followed by HRP-conjugated secondary antibody. Lectin blotting was performed by blocking nitrocellulose transfers with PBS containing 0.05% Tween 20 followed by incubation with 1 µg/ml HRP-conjugated jacalin or peanut agglutinin (EY Labs) in blocking buffer for 1 h at room temperature and extensive washing with PBS. All antibody and lectin staining was detected by enhanced chemiluminescence using Pierce Supersignal Pico West substrate. Gels and chemiluminescence films were imaged using a Bio-Rad GS670 imaging densitometer and the images processed using Bio-Rad Molecular Analyst software (version 1.4) before importation into CorelDraw 10 for figure preparation.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Several laminin isoforms bind {alpha}-dystroglycan (12, 18–21) and induce AChR clustering in myotubes through a mechanism dependent on laminin binding to {alpha}-dystroglycan (9, 22–25). Recent studies (15, 16) further suggest a role for glycoconjugates bearing the core 1 disaccharide Gal{beta}(1–3)GalNAc in AChR clustering on the surface of muscle cells. The lectin jacalin shows specificity for Gal{beta}(1–3)GalNAc but can also bind avidly to SiaA{alpha}(2–3)Gal{beta}(1–3)GalNAc (26). Because {alpha}-dystroglycan is modified by sialylated core 1 disaccharides (see Fig. 2A), we treated C2C12 myotubes with 120 nM laminin-1, 50 µg/ml jacalin, or both and quantitated the number of AChR clusters per field for each treatment (Fig. 1, A and B). Although jacalin alone had no effect on the number of AChR clusters observed relative to untreated control myotubes and laminin-1 alone induced an ~4-fold increase in the number of AChR clusters, jacalin almost completely abrogated laminin-1-induced AChR clustering (Fig. 1B).



View larger version (27K):
[in this window]
[in a new window]
  		FIG. 2.
Jacalin binds to {alpha}-dystroglycan in C2C12 myotubes. Shown in A is the sialylated core 1 oligosaccharide previously identified on {alpha}-dystroglycan. The brackets mark the disaccharide recognized by jacalin and peanut agglutinin (PNA), and the sites of cleavage by neuraminidase (Neur) and endo-O-glycosidase (O-Gly) are marked by arrows. The activity of lectins/enzymes marked by an asterisk requires the absence or enzymatic removal of the terminal sialic acid residue. Shown in B are identical nitrocellulose transfers loaded with control C2C12 myotube lysate and stained with HRP-conjugated jacalin, or monoclonal antibody IIH6 against {alpha}-dystroglycan ({alpha}-DG). Molecular weight standards (x10-3) are indicated on the left. Shown in C are the relative amounts of {alpha}-dystroglycan ({alpha}-DG) and {beta}1 integrin detected on Western blots loaded with equivalent volumes of Triton-solubilized C2C12 lysate (TOT), the jacalin-agarose flow-through (Jac VOID), and jacalin-bound fraction (Jac-Agarose).

 


View larger version (14K):
[in this window]
[in a new window]
  		FIG. 1.
Jacalin lectin inhibits laminin-induced AChR clustering. Shown in A, C2C12 myotubes were treated with 50 µg/ml jacalin (+ Jac), 120 nM laminin-1 (+ Ln-1) or both for 18 h at 37 °C and stained with Alexa488-conjugated bungarotoxin to label AChRs (scale bar is 20 µm). The graph in B reports the average number of AChR clusters observed (± S.E.) in C2C12 myotubes that were either untreated, treated with jacalin, laminin-1, or both jacalin and laminin-1. AChR clusters were counted in 5–10 random fields from each of 2 independent experiments. The number of AChR clusters measured in laminin-1-treated cultures was significantly greater than in control (CON) cultures (p < 0.001), or those treated with jacalin in the absence (p < 0.001), or presence of laminin-1 (p < 0.001) as assessed by ANOVA with Tukey post-test. The number of AChR clusters in control, jacalintreated, and laminin-1 plus jacalin-treated cultures were not significantly different (p > 0.05).

 

To begin to elucidate the mechanism by which jacalin may inhibit laminin-induced AChR clustering, Triton lysates of C2C12 myotubes were resolved by SDS-PAGE, transferred to nitrocellulose and stained with peroxidase-conjugated jacalin. Surprisingly, jacalin detected only a single diffuse band that co-migrated with {alpha}-dystroglycan immunoreactivity (Fig. 2B). We further observed that {alpha}-dystroglycan in C2C12 myotube lysates was not detected in the voids after passage over jacalinagarose and was quantitatively retained on the lectin matrix (Fig. 2C). {alpha}7{beta}1 integrin also mediates laminin-induced AChR clustering (27, 28) and the electrophoretic mobility of the {beta}1 integrin subunit overlaps with that of {alpha}-dystroglycan. However, no {beta}1 integrin in C2C12 myotubes bound to jacalin-agarose (Fig. 2C). From these data, we conclude that jacalin inhibited laminin-1-induced AChR clustering (Fig. 1, A and B) by directly binding to sialylated core 1 oligosaccharides present on {alpha}-dystroglycan.

Because jacalin is bivalent and the number of sialylated core 1 oligosaccharides present on {alpha}-dystroglycan is unknown, we considered the possibility that jacalin inhibited laminin-1-induced AChR clustering by sequestering dystroglycan into cluster-incompetent aggregates on the myotube surface. However, we found that prolonged incubation of C2C12 myotubes with 50 µg/ml jacalin had no effect on the normally diffuse distribution of {beta}-dystroglycan (Fig. 3A).



View larger version (67K):
[in this window]
[in a new window]
  		FIG. 3.
Effect of jacalin on {beta}-dystroglycan distribution and laminin-1 binding to C2C12 myotubes. Shown in A are representative C2C12 myotubes stained with a monoclonal antibody to {beta}-dystroglycan that were untreated (Con) or treated with 50 µg/ml jacalin (+Jac) for 18 h at 37 °C (scale bar is 20 µm). Shown in B are C2C12 myotubes stained with affinity-purified polyclonal antibodies to laminin-1 that were either untreated (Con), or treated with 120 nM laminin-1 in the absence (+Ln-1) or presence of 50 µg/ml jacalin (+Ln-1 + Jac) for 18 h at 37 °C (scale bar is 20 µm). Shown in C is the relative amount of laminin {alpha}1 chain detected on Western blots loaded with equal volumes of SDS-solubilized C2C12 myotube protein that were left untreated (Con), or incubated with 120 nM laminin-1 in the absence (+Ln-1) or presence of 50 µg/ml jacalin (+Ln-1 + Jac) for 18 h at 37 °C.

 

The carbohydrate moieties present on {alpha}-dystroglycan are clearly necessary for its binding to laminins, agrin, and neurexins although the specific oligosaccharides on {alpha}-dystroglycan responsible for its binding to extracellular ligands have not been identified (3). Therefore, jacalin could inhibit laminin-1-induced AChR clustering by blocking laminin-1 binding to {alpha}-dystroglycan. To test this possibility, C2C12 myotubes were either left untreated or incubated with 120 nM exogenous laminin-1 in the absence or presence of 50 µg/ml jacalin, and bound laminin-1 was assessed by two methods. In the first, laminin-1 bound to the myotube surface was assessed qualitatively by immunofluorescence microscopy using an affinity-purified polyclonal antibody raised against laminin-1 (Fig. 3B). Consistent with a previous study (29), we detected virtually no laminin-1 immunoreactivity on the surface of control myotubes, whereas the surfaces of laminin-1-treated myotubes were strongly stained (Fig. 3B). However, surface staining of myotubes incubated with both laminin-1 and jacalin was indistinguishable from that observed for myotubes incubated with laminin-1 alone (Fig. 3B). In the second method, control myotubes and myotubes incubated with laminin-1 in the absence or presence of jacalin were rinsed and solubilized with 1% SDS to extract all protein retained on the culture dish. Western blot analysis of equal amounts of the SDS myotube extracts obtained after each treatment regime revealed an equivalent amount of laminin-1 {alpha}1 chain immunoreactivity retained by cultures incubated with laminin-1 regardless of whether jacalin was present during the incubation period (Fig. 3C).

Although the results presented in Fig. 3, B and C, suggest that jacalin did not inhibit laminin-1-induced AChR clustering by preventing laminin-1 binding to the myotube surface, it remained possible that laminin-1 predominantly binds to myotubes via interaction with {alpha}7{beta}1 integrin but that jacalin subsequently blocks laminin-1 interaction with {alpha}-dystroglycan on the myotube surface. However, we performed two experiments indicating that jacalin was unable to directly block laminin-1 binding to {alpha}-dystroglycan. First, we measured laminin-1 binding to purified {alpha}-dystroglycan immobilized in microtiter wells and measured no effect of jacalin even at concentrations as high as 100 µg/ml (Fig. 4A). As a control, we performed a parallel experiment with monoclonal antibody IIH6, which has previously been shown to block the laminin/{alpha}-dystroglycan interaction (12). As expected, IIH6 completely inhibited laminin-1 binding to immobilized {alpha}-dystroglycan (Fig. 4A) when present at a concentration of 50 µg/ml (63 nM). Given the great molecular weight disparity between jacalin (50,000) and IIH6 IgM (800,000), the data in Fig. 4A indicate that jacalin was unable to inhibit laminin-1 binding to {alpha}-dystroglycan even when present at 500-fold molar excess over laminin-1 and ~30-fold molar excess over the concentration of IIH6 that completely inhibited binding. Finally, we tested whether exogenous laminin-1 could inhibit the binding of C2C12 myotube {alpha}-dystroglycan to jacalin-agarose. Triton-solubilized myotube lysates were pre-incubated with 0, 0.25, or 0.5 µg/ml of purified laminin-1 followed by incubation with jacalin-agarose. We observed similar amounts of {alpha}-dystroglycan retained by jacalinagarose in the absence or presence of added laminin-1 (Fig. 4B). Staining of an identical blot with affinity-purified polyclonal antibodies to laminin-1 revealed that equivalent amounts of laminin {alpha}1 chain were retained by jacalin-agarose (Fig. 4B) even though purified laminin-1 alone exhibited no binding to jacalin-agarose (Fig. 4C). The results of Fig. 4, B and C, indicate that laminin-1 was retained on jacalin-agarose through interaction with {alpha}-dystroglycan in the myotube lysate and that we had saturated all laminin-1 binding sites on {alpha}-dystroglycan. We conclude that laminin-1 and jacalin do not compete for the same or overlapping binding sites on {alpha}-dystroglycan and that the three proteins may form a ternary complex.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 4.
Effect of jacalin on laminin-1 binding to {alpha}-dystroglycan. Shown in A is laminin-1 binding to microtiter wells coated with {alpha}-dystroglycan purified from rabbit skeletal muscle measured in the absence or presence of the indicated concentration of jacalin (open circles) or monoclonal antibody IIH6 (filled circles). Laminin-1 binding is expressed as the percent of binding measured in the absence of added jacalin or IIH6. Shown in B, are the relative amounts of {alpha}-dystroglycan ({alpha}-DG) or laminin {alpha}1 chain bound to jacalin agarose after Tritonsolubilized C2C12 myotube lysates were pre-incubated with 0, 0.25, or 0.5 µg/ml laminin-1. Con, control. Shown in C, is the relative amount of laminin {alpha}1 chain detected on Western blots loaded with equal volumes of purified laminin-1 (Ln-1 TOT), the unbound fraction after incubation with jacalin-agarose (Jac VOID), and the fraction that bound jacalinagarose (Jac-Agarose).

 

Previous studies (15, 16) demonstrated that the enzyme neuraminidase can induce AChR clustering in C2C12 myotubes and that neuraminidase-induced AChR clustering is blocked by the lectin peanut agglutinin. Like jacalin, peanut agglutinin lectin also binds specifically to the core 1 disaccharide but cannot when modified by a terminal sialic acid as expressed on {alpha}-dystroglycan (Fig. 2A). Given that the data in Figs. 1 and 2 suggested that jacalin inhibited laminin-induced AChR clustering by binding to sialylated core 1 oligosaccharides on {alpha}-dystroglycan, we hypothesized that peanut agglutinin may also inhibit neuraminidase-induced AChR clustering by binding to desialylated core 1 disaccharides of neuraminidase-digested {alpha}-dystroglycan. Peroxidase-conjugated peanut agglutinin lectin stained none of the proteins present in control myotube lysates but stained a single diffuse band with an electrophoretic migration that matched that of {alpha}-dystroglycan immunoreactivity in neuraminidase-treated myotubes (Fig. 5A). Peanut agglutinin staining of this single band was substantially decreased when neuraminidase-treated myotubes were simultaneously digested with endo-O-glycosidase (Fig. 5A), which specifically cleaves unmodified core 1 disaccharides from the underlying polypeptide backbone (Fig. 2A). To confirm that the peanut agglutinin-reactive protein in neuraminidase-treated myotubes was indeed {alpha}-dystroglycan, we performed peanut agglutinin-agarose chromatography on control myotube lysates as well as lysates prepared from myotubes digested with neuraminidase in the absence or presence of endo-O-glycosidase. Although {alpha}-dystroglycan in neuraminidase-treated myotubes bound to peanut agglutinin-agarose, no {alpha}-dystroglycan in control lysates was retained by the lectin matrix (Fig. 5B). Moreover, the amount of {alpha}-dystroglycan bound to peanut agglutinin-agarose was dramatically reduced when myotubes were simultaneously incubated with neuraminidase and endo-O-glycosidase (Fig. 5B). These results suggest that peanut agglutinin inhibits neuraminidase-induced AChR clustering by binding to desialylated core 1 disaccharides present on {alpha}-dystroglycan.



View larger version (40K):
[in this window]
[in a new window]
  		FIG. 5.
C2C12 myotube {alpha}-dystroglycan binds peanut agglutinin after digestion with neuraminidase. Shown in A is a Coomassie blue (CB)-stained SDS-polyacrylamide gel of Triton-solubilized C2C12 myotube lysate incubated for 2 h at 37 °C in the absence (Con), or presence of 0.1 units/ml neuraminidase (+Neur) or neuraminidase plus 15 milliunits/ml endo-O-glycosidase (+Neur + O). Also shown are identical nitrocellulose transfers stained with HRP-conjugated peanut agglutinin (PNA) or monoclonal antibody IIH6 against {alpha}-dystroglycan. Molecular weight standards (x10-3) are indicated on the left. Shown in B is a nitrocellulose transfer reporting the amount of {alpha}-dystroglycan bound to peanut agglutinin-agarose from Triton lysates of C2C12 myotubes that were either untreated (Con) or incubated with 0.1 units/ml neuraminidase (+Neur) or neuraminidase plus 15 milliunits/ml endo-O-glycosidase (+Neur + O) for 2 h at 37 °C. Western blotting was performed with IIH6 monoclonal antibody against {alpha}-dystroglycan.

 

If core 1 disaccharides are important for AChR clustering, we reasoned that endo-O-glycosidase treatment should also inhibit neuraminidase-induced AChR clustering. Consistent with previous studies from several labs (15, 17, 30, 31), neuraminidase treatment of C2C12 myotubes caused an ~4-fold increase in the number of clusters observed in comparison with untreated myotubes (Fig. 6). More interestingly, endo-O-glycosidase dramatically inhibited neuraminidase-induced AChR clustering (Fig. 6). When taken together with the results of Martin and colleagues (15, 16), the data in Figs. 5 and 6 indicate that either blocking (by peanut agglutinin) or specific enzymatic removal of core 1 disaccharides from {alpha}-dystroglycan largely abrogates neuraminidase-induced AChR clustering. Although the relevance of neuraminidase-induced AChR clustering in vivo is unclear, these data further support an important role for {alpha}-dystroglycan core 1 disaccharides in AChR clustering, regardless of the mode by which cluster formation is triggered.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 6.
Endo-O-glycosidase inhibits neuraminidase-induced AChR clustering in C2C12 myotubes. C2C12 myotubes were treated with neuraminidase (+Neur) or neuraminidase plus endo-O-glycosidase (+Neur + O) as described above and stained with Alexa488-conjugated bungarotoxin to label AChRs (scale bar is 20 µm). The graph reports the average number of AChR clusters per field (±S.E.) measured in 10 random fields from each of 2 independent experiments. The number of AChR clusters measured in neuraminidase-treated cultures was significantly greater than in control cultures (p < 0.001), or those treated with neuraminidase plus endo-O-glycosidase (p < 0.001) as assessed by ANOVA with Tukey post-test.

 


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Distinct oligosaccharide structures have long been implicated in the process of neuromuscular synaptogenesis based on unique labeling of adult neuromuscular junctions with carbohydrate-specific lectins and antibodies as well as perturbation of AChR clustering in myotube cultures by lectins and glycosidases (15–17, 30–34). With regard to the identity of glycoconjugates bearing sialylated oligosaccharides important in AChR cluster formation, recent data suggests that agrin and MuSK both bind to and are modified by several oligosaccharides that are potentially the site of action by glycosidases and lectins that have been shown to significantly alter AChR clustering in vitro (15, 16). Modulation of agrin and MuSK activity by glycosylation is likely of great physiological relevance because they, along with rapsyn and AChRs, are the core components necessary for AChR cluster formation in vivo (35). Existing evidence suggests that neuraminidase induces AChR clustering in myotubes at least in part by removing sialic acid residues from oligosaccharides present on MuSK (31, 36). Although peanut agglutinin could conceivably inhibit neuraminidase-induced AChR clustering by directly binding to MuSK, Watty and Burden (36) showed that the sialic acid moieties present on MuSK were entirely contained within N-linked oligosaccharides. Moreover, this study observed no binding of peanut agglutinin to MuSK either before or after treatment with neuraminidase (36). These results indicate that neuraminidase does not stimulate AChR clustering by exposing core 1 disaccharides on MuSK, nor does peanut agglutinin block clustering through binding to core 1 disaccharides on MuSK.

In addition to inducing AChR clustering through its action on sialylated N-linked oligosaccharides on MuSK (36), our results demonstrate that neuraminidase treatment also exposes peanut agglutinin-reactive core 1 disaccharides detected predominantly on {alpha}-dystroglycan (Figs. 5 and 6), which suggests that peanut agglutinin exerts its inhibitory effect by binding directly to desialylated {alpha}-dystroglycan. Our experiments with endo-O-glycosidase (Figs. 5 and 6) further indicate that removal of core 1 disaccharides from desialylated {alpha}-dystroglycan is as effective in abrogating neuraminidase-induced AChR clustering as was blocking core 1 disaccharides by peanut agglutinin (15, 16). More importantly, we demonstrated that jacalin also binds predominantly to {alpha}-dystroglycan and effectively inhibits laminin-induced AChR clustering (Figs. 1 and 2) independent of treatment by any glycosidase. These results suggest that the sialylated core 1 oligosaccharides present on native {alpha}-dystroglycan may participate in the formation or stabilization of AChR clusters in vivo. A critical test of this possibility awaits the identification of the {alpha}-dystroglycan amino acids bearing sialylated core 1 oligosaccharides so they can be genetically altered without affecting the O-linked oligosaccharides important for its extracellular ligand binding activities (3).

Because jacalin had no effect on laminin binding to the myotube surface (Fig. 3), or to {alpha}-dystroglycan (Fig. 4), we hypothesize that the sialylated core 1 oligosaccharides of {alpha}-dystroglycan likely perform a novel function in AChR cluster formation that is independent from and likely downstream of the well established role for {alpha}-dystroglycan glycosylation in laminin binding (3). Clusters of core 1 oligosaccharides are generally thought to confer a stiff, extended conformation on the underlying polypeptide backbone (37), and both the extensive glycosylation (3) and electron microscopic evidence (38) support the idea that this may hold true for {alpha}-dystroglycan as well. Therefore, it is conceivable that enzymatic removal of sialylated core 1 oligosaccharides may collapse an extended conformation of {alpha}-dystroglycan that is necessary to transduce laminin binding into some form of downstream signaling. This mechanism is difficult to reconcile with our (Fig. 1) and others' observations (15, 16) that lectin binding to core 1 oligosaccharides also effectively inhibited neuraminidase- and laminin-induced AChR clustering. We instead favor the hypothesis that the sialylated core 1 oligosaccharides of {alpha}-dystroglycan mediates its lateral association with another cell surface or extracellular molecule that is important for AChR cluster formation. Molecules interacting with the sialylated core 1 oligosaccharides of {alpha}-dystroglycan could either stimulate AChR clustering upon binding to {alpha}-dystroglycan, or they may constitutively inhibit clustering until repressed when bound to {alpha}-dystroglycan (35). In this model, either blocking (by lectin binding) or enzymatic removal of the oligosaccharide would be sufficient to abrogate the putative protein-oligosaccharide interaction and disrupt AChR clustering.

Although an obvious candidate for lateral interaction with {alpha}-dystroglycan is {alpha}7{beta}1 integrin (27), we have not been able to detect a biochemical interaction between {alpha}-dystroglycan and {alpha}7{beta}1 integrin even after prolonged incubation of C2C12 myotubes with laminin. Based on its direct binding to and activation by the isolated core 1 disaccharide (15), MuSK can be postulated as a candidate for lateral interaction with {alpha}-dystroglycan. However, the disaccharide Gal{beta}(1–4)GlcNAc also binds to and activates MuSK with the same efficacy as the isolated core 1 disaccharide whereas SiaA{alpha}(2–3)Gal{beta}(1–4)GlcNAc exhibits neither activity (15). Therefore, the lack of specificity of MuSK for core 1 disaccharide, the absence of activity upon sialylation, and the ability of laminin to induce AChR clustering in MuSK-/- myotubes (22) all argue against this possibility and suggests that {alpha}-dystroglycan may laterally associate with a novel cell surface molecule. Fortunately, the results and methodologies described herein provide both the basis and means to identify sialylated core 1 interacting proteins in future experiments.


   FOOTNOTES
 
* This work was supported by the Muscular Dystrophy Association and National Institutes of Health Grant ARO1985 (to J. M. E.) and an American Heart Association-Northland Affiliate Pre-Doctoral Fellowship (to E. L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Dept. of Physiology, University of Wisconsin-Madison, 127 Service Memorial Institute, 1300 University Ave., Madison, WI 53706. Tel.: 608-265-3419; Fax: 608-265-5512; E-mail: ervasti{at}physiology.wisc.edu.

1 The abbreviations used are: AChR, acetylcholine receptor; PBS, phosphate-buffered saline; HRP, horseradish peroxidase; ANOVA, analysis of variance; MuSK, muscle-specific kinase. Back


   ACKNOWLEDGMENTS
 
We thank Drs. Hynda Kleinman and Kevin Campbell for purified laminin-1 and monoclonal antibody IIH6, respectively.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002) Physiol. Rev. 82, 291-329[Abstract/Free Full Text]
  2. Ervasti, J. M. (2003) J. Biol. Chem. 278, 13591-13594[Free Full Text]
  3. Michele, D. E., and Campbell, K. P. (2003) J. Biol. Chem. 278, 15457-15460[Free Full Text]
  4. Cote, P. D., Moukhles, H., Lindenbaum, M., and Carbonetto, S. (1999) Nat. Genet. 23, 338-342[CrossRef][Medline] [Order article via Infotrieve]
  5. Cohn, R. D., Henry, M. D., Michele, D. E., Barresi, R., Saito, F., Moore, S. A., Flanagan, J. D., Skwarchuk, M. W., Robbins, M. E., Mendell, J. R., Williamson, R. A., and Campbell, K. P. (2002) Cell 110, 639-648[CrossRef][Medline] [Order article via Infotrieve]
  6. Henry, M. D., and Campbell, K. P. (1999) Curr. Opin. Cell Biol. 11, 602-607[CrossRef][Medline] [Order article via Infotrieve]
  7. Peng, H. B., Xie, H. B., Rossi, S. G., and Rotundo, R. L. (1999) J. Cell Biol. 145, 911-921[Abstract/Free Full Text]
  8. Grady, R. M., Zhou, H., Cunningham, J. M., Henry, M. D., Campbell, K. P., and Sanes, J. R. (2000) Neuron 25, 279-293[CrossRef][Medline] [Order article via Infotrieve]
  9. Jacobson, C., Cote, P. D., Rossi, S. G., Rotundo, R. L., and Carbonetto, S. (2001) J. Cell Biol. 152, 435-450[Abstract/Free Full Text]
  10. Arikawa-Hirasawa, E., Rossi, S. G., Rotundo, R. L., and Yamada, Y. (2002) Nat. Neurosci. 5, 119-123[CrossRef][Medline] [Order article via Infotrieve]
  11. Ervasti, J. M., and Campbell, K. P. (1991) Cell 66, 1121-1131[CrossRef][Medline] [Order article via Infotrieve]
  12. Ervasti, J. M., and Campbell, K. P. (1993) J. Cell Biol. 122, 809-823[Abstract/Free Full Text]
  13. Bowe, M. A., Deyst, K. A., Leszyk, J. D., and Fallon, J. R. (1994) Neuron 12, 1173-1180[CrossRef][Medline] [Order article via Infotrieve]
  14. Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K., and Sudhof, T. C. (2001) J. Cell Biol. 154, 435-445[Abstract/Free Full Text]
  15. Parkhomovskiy, N., Kammesheidt, A., and Martin, P. T. (2000) Mol. Cell Neurosci. 15, 380-397[CrossRef][Medline] [Order article via Infotrieve]
  16. Xia, B., and Martin, P. T. (2002) Mol. Cell Neurosci. 19, 539-551[CrossRef][Medline] [Order article via Infotrieve]
  17. McDearmon, E. L., Combs, A. C., and Ervasti, J. M. (2001) J. Biol. Chem. 276, 35078-35086[Abstract/Free Full Text]
  18. Gee, S. H., Blacher, R. W., Douville, P. J., Provost, P. R., Yurchenco, P. D., and Carbonetto, S. (1993) J. Biol. Chem. 268, 14972-14980[Abstract/Free Full Text]
  19. Pall, E. A., Bolton, K. M., and Ervasti, J. M. (1996) J. Biol. Chem. 271, 3817-3821[Abstract/Free Full Text]
  20. Ervasti, J. M., Burwell, A. L., and Geissler, A. L. (1997) J. Biol. Chem. 272, 22315-22321[Abstract/Free Full Text]
  21. McDearmon, E. L., Burwell, A. L., Combs, A. C., Renley, B. A., Sdano, M. T., and Ervasti, J. M. (1998) J. Biol. Chem. 273, 24139-24144[Abstract/Free Full Text]
  22. Sugiyama, J. E., Glass, D. J., Yancopoulos, G. D., and Hall, Z. W. (1997) J. Cell Biol. 139, 181-191[Abstract/Free Full Text]
  23. Montanaro, F., Gee, S. H., Jacobson, C., Lindenbaum, M. H., Froehner, S. C., and Carbonetto, S. (1998) J. Neurosci. 18, 1250-1260[Abstract/Free Full Text]
  24. Jacobson, C., Montanaro, F., Lindenbaum, M., Carbonetto, S., and Ferns, M. (1998) J. Neurosci. 18, 6340-6348[Abstract/Free Full Text]
  25. Marangi, P. A., Wieland, S. T., and Fuhrer, C. (2002) J. Cell Biol. 157, 883-895[Abstract/Free Full Text]
  26. Hortin, G. L., and Trimpe, B. L. (1990) Anal. Biochem. 188, 271-277[CrossRef][Medline] [Order article via Infotrieve]
  27. Burkin, D. J., Gu, M., Hodges, B. L., Campanelli, J. T., and Kaufman, S. J. (1998) J. Cell Biol. 143, 1067-1075[Abstract/Free Full Text]
  28. Burkin, D. J., Kim, J. E., Gu, M., and Kaufman, S. J. (2000) J. Cell Sci. 113, 2877-2886[Abstract]
  29. Colognato, H., Winkelmann, D. A., and Yurchenco, P. D. (1999) J. Cell Biol. 145, 619-631[Abstract/Free Full Text]
  30. Martin, P. T., and Sanes, J. R. (1995) Neuron 14, 743-754[CrossRef][Medline] [Order article via Infotrieve]
  31. Grow, W. A., Ferns, M., and Gordon, H. (1999) J. Neurobiol. 40, 356-365[CrossRef][Medline] [Order article via Infotrieve]
  32. Sanes, J. R., and Cheney, J. M. (1982) Nature 300, 646-647[CrossRef][Medline] [Order article via Infotrieve]
  33. Scott, L. J. C., Bacou, F., and Sanes, J. R. (1988) J. Neurosci. 8, 932-944[Abstract]
  34. Martin, P. T., Scott, L. J., Porter, B. E., and Sanes, J. R. (1999) Mol. Cell Neurosci. 13, 105-118[CrossRef][Medline] [Order article via Infotrieve]
  35. Sanes, J. R., and Lichtman, J. W. (2001) Nat. Rev. Neurosci. 2, 791-805[Medline] [Order article via Infotrieve]
  36. Watty, A., and Burden, S. J. (2002) J. Biol. Chem. 277, 50457-50462[Abstract/Free Full Text]
  37. van den, S. P., Rudd, P. M., Dwek, R. A., and Opdenakker, G. (1998) Crit Rev. Biochem. Mol. Biol. 33, 151-208[CrossRef][Medline] [Order article via Infotrieve]
  38. Brancaccio, A., Schulthess, T., Gesemann, M., and Engel, J. (1995) FEBS Lett. 368, 139-142[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
J. M. Rojek, C. F. Spiropoulou, K. P. Campbell, and S. Kunz
Old World and Clade C New World Arenaviruses Mimic the Molecular Mechanism of Receptor Recognition Used by {alpha}-Dystroglycan's Host-Derived Ligands
J. Virol., June 1, 2007; 81(11): 5685 - 5695.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Harrison, S.-A. Hussain, A. C. Combs, J. M. Ervasti, P. D. Yurchenco, and E. Hohenester
Crystal Structure and Cell Surface Anchorage Sites of Laminin {alpha}1LG4-5
J. Biol. Chem., April 13, 2007; 282(15): 11573 - 11581.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. R. Tremblay and S. Carbonetto
An Extracellular Pathway for Dystroglycan Function in Acetylcholine Receptor Aggregation and Laminin Deposition in Skeletal Myotubes
J. Biol. Chem., May 12, 2006; 281(19): 13365 - 13373.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. K. Patnaik and P. Stanley
Mouse Large Can Modify Complex N- and Mucin O-Glycans on {alpha}-Dystroglycan to Induce Laminin Binding
J. Biol. Chem., May 27, 2005; 280(21): 20851 - 20859.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. C. Trinidad and J. B. Cohen
Neuregulin Inhibits Acetylcholine Receptor Aggregation in Myotubes
J. Biol. Chem., July 23, 2004; 279(30): 31622 - 31628.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/45/44868    most recent
M307026200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDearmon, E. L.
Right arrow Articles by Ervasti, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDearmon, E. L.
Right arrow Articles by Ervasti, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement